<br>        Inclusion Criteria:<br><br>          -  Adult males and females between 18 and 55 years of age (inclusive) with total body<br>             weight between 50.0 and 100.0 kilogram (kg) (inclusive) and body mass index (BMI)<br>             between 19.0 and 30.0 kilogram per meter square (kg/m2) (inclusive) at the time of the<br>             Screening examination.<br><br>          -  A female participant is eligible to participate if she is not pregnant, not<br>             breastfeeding.<br><br>          -  Females must have a negative serum pregnancy test at Screening visit and at Day -1<br>             before randomization/first dosing.<br><br>          -  Men must agree to use a barrier method (specifically, male condom with or without<br>             spermicide) and to have their female partners use a highly effective method of<br>             contraception during the treatment period, and for at least 3 months after the last<br>             IMP administration. Men must also refrain from donating sperm during this period.<br><br>          -  Healthy as assessed by the Investigator with no clinically significant abnormality<br>             identified on physical examination or laboratory evaluation and no active clinically<br>             significant disorder, condition, infection or disease that would pose a risk to<br>             subject safety or interfere with the trial evaluation, procedures, or completion.<br><br>          -  Stable non-smokers for at least 3 months preceding Screening.<br><br>          -  Must agree not to consume any alcohol during the treatment period of the trial.<br><br>          -  Able and willing to give written informed consent and has signed the appropriate<br>             written informed consent form, approved by the Investigator's Independent Ethics<br>             Committee (IEC), prior to the performance of any trial activities.<br><br>        Exclusion Criteria:<br><br>          -  History of clinically relevant disease of any organ system, that may interfere with<br>             the objectives of the trial or provide a risk to the health of the subject.<br><br>          -  History of chronic or recurrent acute infection or any bacterial, viral, parasitic or<br>             fungal infections within 30 days prior to Screening and at any time between Screening<br>             and admission, or hospitalization due to infection within 6 months prior to Screening.<br><br>          -  History of Herpes zoster within 12 months prior to Screening<br><br>          -  History of drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity<br>             to the active drug substance and/or formulation ingredients; history of serious<br>             allergic reactions leading to hospitalization or any other hypersensitivity reaction<br>             in general, which may affect the safety of the subject and/or outcome of the trial per<br>             the Investigator's discretion.<br><br>          -  History of alcoholism or drug abuse within 2 years prior to Screening and the subject<br>             is unwilling to abstain from alcohol and drug of abuse during the trial<br><br>          -  Consumption of an average weekly intake of greater than (>) 14 drinks/week for males<br>             or > 7 drinks/week for females. One drink is equivalent to (12 g alcohol) = 5 ounces<br>             (150 milliliter (mL)) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of<br>             40 Vol% distilled spirits.<br><br>          -  Positive for drugs of abuse, nicotine/cotinine or alcohol at Screening or at<br>             admission.<br><br>          -  Supine systolic blood pressure > 140 mmHg or less than (<) 90 mmHg, diastolic blood<br>             pressure > 90 mmHg or <50 and pulse rate >100 or = 50 bpm, at admission.<br><br>          -  12-Lead ECG showing a QTcF > 450 ms, PQ > 200ms, or QRS > 120 ms or other clinically<br>             relevant abnormal findings<br>